The Recombinant DNA (rDNA) Technology Market is projected to register a CAGR of about 6.8% during the forecast period.
The COVID-19 pandemic has been having a positive impact on the market studied, as this is increasing the demand for Recombinant DNA technology in the development of therapeutics and diagnostics. For instance, in November 2020, a research paper published in the United States National Library of Medicine named “Recombinant vaccines for COVID-19" stated that the recombinant COVID-19 vaccine has the capability to overcome limitations and the safety concerns associated with other vaccines. Many Covid -19 vaccines have been manufactured by several companies. On 30 December 2020, the Oxford-AstraZeneca COVID-19 vaccine was one of the first approved for use in the United Kingdom vaccination program, and the first vaccination outside of a trial was administered on 4 January 2021. As of January 2022, more than 2.5 billion doses of the vaccine have been released to more than 170 countries worldwide.
Recombinant DNA technology (RDT) is essential for improving health conditions, primarily by developing new vaccines and pharmaceuticals. Moreover, the treatment strategies are improved by developing diagnostics kits, monitoring devices, and new therapeutic approaches. Additionally, many other industries are benefiting from the research conducted on genetically modified organisms (GMO), such as microorganisms that are considered as clean fuel producers and bio degraders. Genetically modified vaccines are developed for curing various diseases in humans and plants. The recombinant DNA technology created several potential innovation opportunities for developing a wide range of therapeutic products, with immediate effect in medical genetics and biomedicine, by modifying microorganisms, animals, and plants, in order to yield medically useful substances. Product launches are another factor for the growth of the market. For instance, in September 2021, A Tokyo-based startup called Sanatech Seed Co. teamed up with scientists at the University of Tsukuba to develop a new variety of tomatoes with the help of CRISPR/Cas9 gene-editing technology. The first product offered was seeds, delivered free of charge to around 4,200 people. Now, the company has started selling genetically modified tomatoes. Such launches will increase the growth of the market in upcoming future.
Therefore, the increasing demand and application of RDT in various sectors are driving the growth of the market studied. However, regulatory, ccientific, and ethical challenges associated with gene therapy may restrain the growth of market.
In agriculture, the development of genetically modified crops, in order to improve both yield and resistance to pests or herbicides, is gaining a high degree of public acceptance. The genetically modified tomato, CGN-89564-2, was one of the first commercially grown, genetically engineered crop product to be granted a license for human consumption. Additionally, DNA molecular marker technology is important for the preservation, identification, evaluation, mining, and innovation of plant germplasm resources.
The introduction of genetically modified fruit paved the way for the use of GMOs in food. Currently, genetic modification is witnessing widespread adoption. Similarly, China plans an overhaul of its seed rules that will pave way for GMO approvals. It is a big step for China’s modern agriculture and a new business opportunity for upstream ag input suppliers. In July 2021, the 20th meeting of the Commission for Deepening Overall Reform of the China Central Committee deliberated and approved the “Action Plan for Revitalizing the Seed Industry.” It provides insight into China showing significant importance on the innovations brought on by biological breeding, especially the R&D and industrialization of genetically modified organisms (GMO). Due to these approvals, the segment is likely to grow in the future.
Initiatives by public and private organizations are one of the key factors for the growth of the market. For instance, in August 2021, Corteva, Inc. launched a genetically modified Conkesta E3 soybean seed in the Brazilian market. The soybeans recently received authorization by the European Union Commission, which enables grain produced from Conkesta E3 soybean seeds grown in Brazil to be exported to the European market for food and feed use.
Thus, increasing the application of RDT in agriculture and food is expected to drive the growth of the market studied.
The North American region is expected to dominate the market studied over the forecast period. In the North American region, the United States accounts for the largest market share, primarily due to the presence of numerous biopharmaceutical manufacturing companies and the presence of effective regulatory bodies to monitor the various ethical and scientific concerns, pertaining to the use of technology. This is expected to drive the market’s growth, especially in the North American region.
The Increasing number of diseases such as HIV is another factor for the growth of the market in the region. In 2019, according to the Centers for Disease Control and Prevention 36,801 people received an HIV diagnosis in the United States. The same source stated that around 1,189,700 people had HIV during the same period. Since recombinant DNA technology is used for the treatment of HIV the market will grow in the future.
Similarly, various research studies are another reason for the growth of the market. For instance, in September 2021, a research study published in the United States National Library of Medicine titled "Review of Poultry Recombinant Vector Vaccines" stated that The control of poultry diseases has relied heavily on the use of many live and inactivated vaccines. However, over the last 30 yr, recombinant DNA technology has been used to generate many novel poultry vaccines. Fowlpox virus and turkey herpesvirus are the two main vectors currently used to construct recombinant vaccines for poultry. With the use of these two vectors, more than 15 recombinant viral vector vaccines against Newcastle disease, infectious laryngotracheitis, infectious bursal disease, avian influenza, and Mycoplasma gallisepticum have been developed and are commercially available. With the increasing research studies to support the market growth the market is likely to grow in the future.
Hence, due to the above-mentioned factors, the market is likely to increase in the future and North America is likely to dominate the market.
The Recombinant DNA (rDNA) Technology market is competitive, with the presence of both major players and small players. In terms of market share, the major players are currently dominating the market. Some of the major market players include GenScript, New England Biolabs, GlaxoSmithKline Plc, Pfizer, and Sanofi, among others.
This product will be delivered within 2 business days.
The COVID-19 pandemic has been having a positive impact on the market studied, as this is increasing the demand for Recombinant DNA technology in the development of therapeutics and diagnostics. For instance, in November 2020, a research paper published in the United States National Library of Medicine named “Recombinant vaccines for COVID-19" stated that the recombinant COVID-19 vaccine has the capability to overcome limitations and the safety concerns associated with other vaccines. Many Covid -19 vaccines have been manufactured by several companies. On 30 December 2020, the Oxford-AstraZeneca COVID-19 vaccine was one of the first approved for use in the United Kingdom vaccination program, and the first vaccination outside of a trial was administered on 4 January 2021. As of January 2022, more than 2.5 billion doses of the vaccine have been released to more than 170 countries worldwide.
Recombinant DNA technology (RDT) is essential for improving health conditions, primarily by developing new vaccines and pharmaceuticals. Moreover, the treatment strategies are improved by developing diagnostics kits, monitoring devices, and new therapeutic approaches. Additionally, many other industries are benefiting from the research conducted on genetically modified organisms (GMO), such as microorganisms that are considered as clean fuel producers and bio degraders. Genetically modified vaccines are developed for curing various diseases in humans and plants. The recombinant DNA technology created several potential innovation opportunities for developing a wide range of therapeutic products, with immediate effect in medical genetics and biomedicine, by modifying microorganisms, animals, and plants, in order to yield medically useful substances. Product launches are another factor for the growth of the market. For instance, in September 2021, A Tokyo-based startup called Sanatech Seed Co. teamed up with scientists at the University of Tsukuba to develop a new variety of tomatoes with the help of CRISPR/Cas9 gene-editing technology. The first product offered was seeds, delivered free of charge to around 4,200 people. Now, the company has started selling genetically modified tomatoes. Such launches will increase the growth of the market in upcoming future.
Therefore, the increasing demand and application of RDT in various sectors are driving the growth of the market studied. However, regulatory, ccientific, and ethical challenges associated with gene therapy may restrain the growth of market.
Key Market Trends
The Food and Agriculture segment is Expected to Register the High CAGR Growth Over the Forecast period
In agriculture, the development of genetically modified crops, in order to improve both yield and resistance to pests or herbicides, is gaining a high degree of public acceptance. The genetically modified tomato, CGN-89564-2, was one of the first commercially grown, genetically engineered crop product to be granted a license for human consumption. Additionally, DNA molecular marker technology is important for the preservation, identification, evaluation, mining, and innovation of plant germplasm resources.
The introduction of genetically modified fruit paved the way for the use of GMOs in food. Currently, genetic modification is witnessing widespread adoption. Similarly, China plans an overhaul of its seed rules that will pave way for GMO approvals. It is a big step for China’s modern agriculture and a new business opportunity for upstream ag input suppliers. In July 2021, the 20th meeting of the Commission for Deepening Overall Reform of the China Central Committee deliberated and approved the “Action Plan for Revitalizing the Seed Industry.” It provides insight into China showing significant importance on the innovations brought on by biological breeding, especially the R&D and industrialization of genetically modified organisms (GMO). Due to these approvals, the segment is likely to grow in the future.
Initiatives by public and private organizations are one of the key factors for the growth of the market. For instance, in August 2021, Corteva, Inc. launched a genetically modified Conkesta E3 soybean seed in the Brazilian market. The soybeans recently received authorization by the European Union Commission, which enables grain produced from Conkesta E3 soybean seeds grown in Brazil to be exported to the European market for food and feed use.
Thus, increasing the application of RDT in agriculture and food is expected to drive the growth of the market studied.
The North American region is Expected to Dominate the Market Over the Forecast Period
The North American region is expected to dominate the market studied over the forecast period. In the North American region, the United States accounts for the largest market share, primarily due to the presence of numerous biopharmaceutical manufacturing companies and the presence of effective regulatory bodies to monitor the various ethical and scientific concerns, pertaining to the use of technology. This is expected to drive the market’s growth, especially in the North American region.
The Increasing number of diseases such as HIV is another factor for the growth of the market in the region. In 2019, according to the Centers for Disease Control and Prevention 36,801 people received an HIV diagnosis in the United States. The same source stated that around 1,189,700 people had HIV during the same period. Since recombinant DNA technology is used for the treatment of HIV the market will grow in the future.
Similarly, various research studies are another reason for the growth of the market. For instance, in September 2021, a research study published in the United States National Library of Medicine titled "Review of Poultry Recombinant Vector Vaccines" stated that The control of poultry diseases has relied heavily on the use of many live and inactivated vaccines. However, over the last 30 yr, recombinant DNA technology has been used to generate many novel poultry vaccines. Fowlpox virus and turkey herpesvirus are the two main vectors currently used to construct recombinant vaccines for poultry. With the use of these two vectors, more than 15 recombinant viral vector vaccines against Newcastle disease, infectious laryngotracheitis, infectious bursal disease, avian influenza, and Mycoplasma gallisepticum have been developed and are commercially available. With the increasing research studies to support the market growth the market is likely to grow in the future.
Hence, due to the above-mentioned factors, the market is likely to increase in the future and North America is likely to dominate the market.
Competitive Landscape
The Recombinant DNA (rDNA) Technology market is competitive, with the presence of both major players and small players. In terms of market share, the major players are currently dominating the market. Some of the major market players include GenScript, New England Biolabs, GlaxoSmithKline Plc, Pfizer, and Sanofi, among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd (Genentech Inc.)
- GenScript
- Horizon Discovery
- Merck KGaA
- New England Biolabs
- Novartis AG
- Novo Nordisk A/S
- Pfizer Inc.
- Sanofi
- Syngene International Limited
Methodology
LOADING...
